Glutathione transferase P1-1 as an arsenic drug-sequestering enzyme.
Michael W ParkerAlessio BocediDavid B AscherJade B AitkenHugh H HarrisMario Lo BelloGiorgio RicciCraig J MortonMichael W ParkerPublished in: Protein science : a publication of the Protein Society (2016)
Arsenic-based compounds are paradoxically both poisons and drugs. Glutathione transferase (GSTP1-1) is a major factor in resistance to such drugs. Here we describe using crystallography, X-ray absorption spectroscopy, mutagenesis, mass spectrometry, and kinetic studies how GSTP1-1 recognizes the drug phenylarsine oxide (PAO). In conditions of cellular stress where glutathione (GSH) levels are low, PAO crosslinks C47 to C101 of the opposing monomer, a distance of 19.9 Å, and causes a dramatic widening of the dimer interface by approximately 10 Å. The GSH conjugate of PAO, which forms rapidly in cancerous cells, is a potent inhibitor (Ki = 90 nM) and binds as a di-GSH complex in the active site forming part of a continuous network of interactions from one active site to the other. In summary, GSTP1-1 can detoxify arsenic-based drugs by sequestration at the active site and at the dimer interface, in situations where there is a plentiful supply of GSH, and at the reactive cysteines in conditions of low GSH.
Keyphrases
- fluorescent probe
- drinking water
- mass spectrometry
- high resolution
- heavy metals
- induced apoptosis
- crispr cas
- photodynamic therapy
- emergency department
- single molecule
- computed tomography
- magnetic resonance imaging
- risk assessment
- neoadjuvant chemotherapy
- ms ms
- cancer therapy
- magnetic resonance
- signaling pathway
- drug delivery
- cell death
- dual energy